Vigonvita Issues Supplemental Results Disclosure After HK$16.00 Million IPO Funds Were Misallocated to Unlisted Fund

Vigonvita Life Sciences Co., Ltd. (Vigonvita) released a supplemental announcement to its 2025 annual results, clarifying the unintended use of HK$16.00 million (approximately RMB14.42 million) in net proceeds from its 2025 Global Offering.

In January 2026, the Group made two investments in unlisted market funds managed by independent third parties:

• First Subscription: HK$35.12 million (approximately RMB31.55 million) funded by internal resources. • Second Subscription: HK$16.00 million (approximately RMB14.42 million) mistakenly paid with IPO proceeds.

The Board attributed the misallocation to an oversight within the finance department, which failed to detect insufficient own funds in the relevant account and mistakenly regarded the investment as a permissible deposit under the Prospectus. Upon detection, Vigonvita redeemed the Second Subscription in full.

To prevent recurrence, the Company has adopted the following corrective measures: 1. Legal advisers will conduct targeted training for finance, accounting, and senior management on disclosure and regulatory requirements. 2. Quarterly training for finance staff and semi-annual and annual sessions for senior management and Directors, respectively, covering Listing Rules, disclosure obligations, and risk controls. 3. An enhanced Office Automation workflow now mandates finance-department clearance for any transaction of RMB2.00 million or above to verify funding sources and ensure IPO proceeds are applied strictly to disclosed purposes. 4. Mandatory pre-transaction consultation with the compliance adviser and joint company secretaries for all future wealth-management product purchases.

The Company confirmed that all IPO proceeds will ultimately be deployed in line with the intended purposes set out in the Prospectus. Both fund subscriptions and the subsequent redemption fall below the 5% threshold of the size tests under Chapter 14 of the Listing Rules, so they do not constitute discloseable transactions.

The supplemental disclosure does not impact any other information contained in Vigonvita’s 2025 annual results published on 31 March 2026.